Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma.
Fiche publication
Date publication
avril 2023
Journal
Journal of gastrointestinal oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie, Dr DROUILLARD Antoine, Pr GHIRINGHELLI François, Pr LEPAGE Côme, Dr VINCENT Julie, Pr MANFREDI Sylvain, Dr BENGRINE-LEFEVRE Leila, Dr HENNEQUIN Audrey
Tous les auteurs :
Piquemal D, Bruno R, Bournet B, Ghiringhelli F, Noguier F, Canivet C, Bertaut A, Pierrat F, Evesque L, Gamez A, Cros J, Rederstorff E, Petit E, Adnet J, Saint A, Drouillard A, Kempf E, Soularue E, Vincent J, Baumgaertner I, Hennequin A, Tournigand C, Lopez Trabada Ataz D, Bengrine L, Lepage C, Manfredi S, Afchain P, Trouilloud I, Gagnaire A, LoConte NK, Bachet JB
Lien Pubmed
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, and chemotherapy is a key treatment for advanced PDAC. Gemcitabine chemotherapy is still an important component of treatment; however, there is no routine biomarker to predict its efficacy. Predictive tests may help clinicians to decide on the best first-line chemotherapy.
Mots clés
Pancreatic cancer, gemcitabine-based, liquid biopsy, predictive diagnosis
Référence
J Gastrointest Oncol. 2023 04 29;14(2):997-1007